Clinical Trial · NCT00464282

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

Overview

Objective: L-\[3-18F\]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated. Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.

Sponsor

Indiana University

Contacts

kyoichi kaira, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00464282

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

FMT

Isotope(s):

Target(s):

L-type amino acid transporter 1 (LAT1)

Ligand Class: Small Molecules

Eligibility

Inclusion

* proven or suspected non-small cell lung cancer

Exclusion

* uncontrolled diabetes mellitus